Why I believe these 3 stocks will struggle in 2017

These three companies are in danger of generating losses for investors next year.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

2017 is just around the corner and City analysts are picking their top stocks for the 12 months ahead. As well as the stocks I’m betting on for 2017, there are some companies I want to avoid next year as headwinds for these firms grow.

Indeed, I believe shares in Reckitt Benckiser (LSE: RB) will come under pressure next year as so-called ‘bond proxy’ stocks continue to fall out of favour with investors. 

Bond proxies are equities that have become an alternative to bonds as interest rates on bonds plunge into negative territory. Defensive companies such as Reckitt are prime proxies as their cash flows are considered safe, helping long-term dividend sustainability. However, as bond yields around the world are now pushing higher, these bond proxies are becoming less popular. 

It’s easy to see why. Yes, these are high-quality businesses, but the reach for yield has pushed their valuations up to record levels. Shares in Reckitt currently trade at a forward P/E of 22.9, down from last year’s 23.9 but still far above peer Unilever’s 19.7. I expect Reckitt’s shares to fall next year as investors rebalance away from bond proxies back towards bonds.

Revenues falling 

AstraZeneca (LSE: AZN) is another company I’m avoiding for 2017. This year, Astra’s most successful drug Crestor came off patent, and the full extent of this patent expiry isn’t yet known. 

According to City consensus, Astra’s top line is expected to fall by 5.8% next year due to management inability to rekindle the company’s pipeline growth. During the third quarter of this year, total product sales were down by 14% at $5bn, as Crestor and Nexium sales declined by 82% and 50% respectively in the US. For the quarter, the company reported a $1bn loss but earnings per share rose 4% to $0.80 thanks to a $453m tax benefit. 

As Astra’s earnings continue to contract with falling sales, it may be wise to avoid the drug maker next year.

Profits evaporate 

Finally, Rolls-Royce (LSE: RR) is a struggling engineer I’m avoiding next year. It has plenty of problems. From falling marine sales as a result of the oil price collapse, to faulty engines delivered to one of its largest customers Emirates, Rolls-Royce is struggling to get things right. What’s more, a new accounting change, whereby the company can’t immediately recognise revenue generated over the life of its engine service contracts immediately, will decimate profitability next year. Under the new accounting rules, Rolls’ 2015 profits would have been £900m lower than the £1.4bn reported. It’s not entirely clear how this change will impact profitability next year, but it’s evident the company will take a big hit to earnings. 

With profits set to tank and problems for the group brewing, Rolls might be one to avoid next year.

Rupert Hargreaves owns shares of Rolls-Royce. The Motley Fool UK owns shares of and has recommended Unilever. The Motley Fool UK has recommended AstraZeneca and Reckitt Benckiser. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Businessman with tablet, waiting at the train station platform
Investing Articles

By March 2027, £1,000 invested in Natwest shares could turn into…

NatWest shares have been on a tear in recent years. What might the next 12 months have in store for…

Read more »

many happy international football fans watching tv
Investing Articles

With a P/E of 6.6, does this FTSE 100 stock offer amazing value?

Despite appearing to offer tremendous value, investors are overlooking this well-known FTSE 100 stock. James Beard looks at the reasons…

Read more »

A senior man using hiking poles, on a hike on a coastal path along the coastline of Cornwall. He is looking away from the camera at the view.
Investing Articles

Buying 56,476 shares in this FTSE 100 dividend stock could double the State Pension

Harvey Jones crunches the numbers to show how much he needs to hold in one top dividend stock to generate…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

This FTSE 250 stock’s crashed 18% today! Is it too cheap to miss?

Vistry is one of the FTSE 250's worst-performing stocks, sinking by double-digit percentages on Wednesday (4 March). Is this a…

Read more »

ISA Individual Savings Account
Investing Articles

How much do I need in a Stocks and Shares ISA to earn a £100 monthly income?

A 6% dividend yield's enough to turn £20,000 into a £100 monthly income for investors using a Stocks and Shares…

Read more »

Calendar showing the date of 5th April on desk in a house
Investing Articles

It’s ISA time – but would your money work harder in a SIPP? I asked ChatGPT…

As the annual Stocks and Shares ISA deadline looms, Harvey Jones asks if investors would be better off putting money…

Read more »

Investing Articles

Up 42% in 12 months! Why I like this dividend share yielding 5%

This FTSE 100 dividend share has soared higher while still maintaining a dividend yield of 5%. Ken Hall takes a…

Read more »

Burst your bubble thumbtack and balloon background
Investing Articles

£15,000 invested in Helium One shares in December 2020 is now worth…

James Beard explains why loyal Helium One shareholders will be hoping the group can soon commercialise gas production.

Read more »